The company states the acquisition will further MERIT’s service offerings, allowing for a seamless transition from ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

While the wet AMD market is highly competitive, with established therapies such as Eylea, Vabysmo, and Lucentis dominating, Opthea Limited (NASDAQ:OPT) is positioning sozinibercept as a ...

Brolucizumab is a follow-up to Novartis’ blockbuster AMD therapy Lucentis (ranibizumab), which has been competing toe-to-toe in the AMD market with Eylea for several years. Novartis reported ...

We recently compiled a list of the 10 Best Australian Stocks to Buy Now. In this article, we are going to take a look at ...

Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon's biosimilar to Lucentis ® 2 ... Formycon's biosimilar candidate to Eylea ® (aflibercept ...

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...

Canaccord rates Opthea a buy with a $1.25 price target. But the broker thinks it could shoot as high as $3 if a key trial ...

Diabetic Macular Edema MarketThe global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

a biosimilar candidate to Eylea® (aflibercept), in Europe (excluding Italy) and Israel. This partnership builds upon their successful collaboration on FYB201, a biosimilar for Lucentis®.

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...